recipients were observed without any intervention (non-vaccine group). Eight of the 13 historical control group recipients and 3 of the 12 non-vaccine group recipients, but none of the 13 vaccine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historical control, non-vaccine and vaccine groups were 41%, 39% and 0% respectively (P=0.022). We therefore conclude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS.
Introduction
Hematopoietic stem cell transplantation (HSCT) is performed worldwide to treat various diseases, including hematological malignancies.
Intensive chemotherapy and immunosuppression, in patients who undergo HSCT, result in immune dysfunction putting these patients at high risk for infection, not only with external pathogens but also internal ones. Reactivation of herpes viruses such as Herpes simplex (HSV), Varicella zoster (VZV), Human Herpes Virus 6 (HHV6), Epstein-Barr (EBV), and Cytomegalovirus (CMV), for instance, are well-known phenomena in such patients; recently hepatitis B virus (HBV)
has also been recognized to be reactivated following HSCT.
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The appearance of anti-hepatitis B surface antigen antibody (anti-HBs) and the clearance of HBV from the serum usually indicate resolution of hepatitis in patients infected with HBV.
However, most patients in whom HBV has been eliminated from the serum still have HBV DNA in the liver that is detectable by polymerase chain reaction (PCR). 5 Reactivation of dormant HBV in the liver has been observed in an immunocompromised status, such as HSCT, renal transplantation, intensive chemotherapy or rituximab use.
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The reactivation of hepatitis in anti-HBs positive patients is known as reverse seroconversion (RS). Previously, we have revealed that RS is a late-onset complication with high frequency that can be predicted by careful monitoring of the progressive disappearance of anti-HBs. 1 From earlier observations, we consider that RS hepatitis after HSCT is a hepatitis caused by reconstituted naïve donor immunity, following the loss of recipient-derived immunity against HBV.
In the current study, we conducted post-transplant recombinant HB (rHB) vaccine intervention to immunize naïve donor immunity and to determine its clinical efficacy in preventing post-transplant HBV-RS.
Patients and Methods
Patients Studied. Allo-HSCT recipients who underwent transplantation in our hospital, from February 1990 to March 2007, and who were followed for at least 1 year after HSCT, were enrolled in this study. We retrospectively studied 38 recipients with previous HBV infection in the pre-HSCT evaluation. We started hepatitis B vaccine intervention in HSCT HSCT, immunity is reconstituted and treatment with immunosuppressants can be stopped.
We therefore hypothesized that active immunization by rHB vaccine might be useful in avoiding HBV-RS after HSCT. The safety and efficacy of rHB vaccination in HSCT recipients has already been reported. 18 Some guidelines for post-transplant vaccination recommend rHB vaccination, mainly to prevent de novo infection of HBV from outside the body. It was the European Group for Blood and Marrow Transplantation (EBMT), which for the first time, proposed the use of rHB vaccination to prevent innate HBV reactivation as a post-transplant vaccination option. 19 The clinical efficacy of the rHB vaccine in preventing post-transplant HBV-RS, however has not been previously reported. Notwithstanding that this study is a non-randomized historical case-control study, this is the first report in which the usefulness of HB vaccine in preventing HBV-RS after HSCT has been investigated.
Several studies have recommended prophylactic vaccination of the donor, expecting adoptive transfer of HBV immunity; a well-described phenomenon in the literature [9] [10] [11] 14 , regrettably however, attempts to overcome immunodeficiency by immunizing the donor have not always been successful. 4, 20 Long-term immunity, defined as the persistence of antibody presence, is not achieved without re-exposure to the specific antigen, either by re-immunization or re-infection, regardless of the immune status of the donor. 3, 20 In our study, the rate of successful vaccinations was lower than that described in a previous report. 18 Interestingly, however, in our study 4 of the 9 non-responders (44%) showed a slight increase in their anti-HBs titer after HB vaccination, even though the responder criteria (>10 mIU/ml) were not met. Consequently, in non-responders, an intensified dose or schedule, possibly using another rHB vaccine should be taken into consideration.
In conclusion, RS is a late-onset complication with high frequency following HSCT, which can be predicted by careful monitoring of the progressive disappearance of anti-HBs. In view of the results obtained in this study we propose rHB vaccination of recipients as a valuable prophylactic tool for the reactivation of HBV in allo-HSCT patients. The primary endpoint was the occurrence of RS. The actual risks of the endpoints were estimated using the Kaplan-Meier method. Survival curves were compared using the log-rank test. There were no differences between the 'Historical control group' and the 'Non-vaccine group' (P=0.74). The 'Vaccine group' showed a significantly lower risk for HBV-RS than the other two groups (P=0.022).
